Gordon  McLennan,  M.D.

Gordon McLennan, M.D.


Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Location: ND3-28
Email: mclenng@ccf.org
Phone: (216) 444-6124
Fax: (216) 445-1492


The primary focus of our research is on how to more effectively deliver drugs to cancer without damaging normal tissues nearby. This includes research in sustained drug delivery, new drug systems with lower toxicity, as well as combinations of imaging, ablation technologies, and drug delivery techniques to improve tumor kill or destroy painful tumors while preserving normal function. We also focus on developing a fundamental understanding of the tumor microenvironment including the role of the hepatic stellate cells in the progression of primary liver cancer. We have demonstrated that when hepatic stellate cells are in their Quiescent state, they produce factors which inhibit HCC growth & metastasis. We are endeavoring to identify what those molecules are in hopes of developing new therapies for HCC. In the area of drug delivery, the lab was recently awarded the Pink Gardenia award from the Breast Cancer Research Foundation in Akron for the work we did characterizing the cellular uptake of nanoparticles in breast cancer cell lines.

In other words ...

Interventional Radiology (IR) is a very diverse field that touches on all aspects of medicine. The unifying theme of IR is the use of x-ray, ultrasound, or MRI imaging to guide treatments. Interventional Radiologists treat stroke, aneurysms, vascular disease, cancer, uterine fibroids, painful cancers and non-cancerous tumors as well as take care of patients on dialysis or with clot in their legs. The focus of our laboratory's research is in the field of liver cancers. Primary liver cancer is the fastest growing cancer in the United States & while current treatments have prolonged people's lives from less than 1 year to 2-3 years, there is much that needs to be done. Our research focuses on new drugs that are less toxic than current drugs & ways to deliver the drugs directly to the tumors through the blood vessels that feed them. If we can deliver less toxic drugs with more specific treatment methods, we should be able to prolong the lives of people with liver cancer.

McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, Sands M, Narayanan Menon KV, Aucejo FN, Estfan B, Pillai AK, Kalva SP, McLennan G. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. JVIR (2017) 28(10):1371-1377. PMID:

Klungboonkrong V, Das D, McLennan G. Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma. JVIR (2017) 28:7 949-955. PMID: 28416267

Murali AR; Romero-Marrero C; Miller C; Aucejo F; Levitin A; Gill A; McLennan G; Karuppasamy K; Zein NN; Lopez R; Menon KV. Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria. Transplantation. 100(11):2391-2397, 2016 Nov. PMID: 27780187

28689934Boules M, Haskins IN, Farias-Kovac M, Guerron AD, Schechtman D, Samotowka M, O’Rourke CP, McLennan G, Walsh RM, and Morris-Stiff G. "What is the fate of the cholecystostomy tube following percutaneous cholecystostomy?." Surgical Endoscopy (2016): 1-6. PMID 27519595

Babsky AM, Ju S, George B, Bennett S, Huang M, Jayaram HN, McLennan G, Bansal N. Predicting response to benzamide riboside chemotherapy in hepatocellular carcinoma using apparent diffusion coefficient of water. Anticancer Research. 31(6):2045-51, 2011 Jun.

Lance C, McLennan G, Obuchowski N, Cheah G, et. al. Comparative Analysis of the Safety and Efficacy of Transcatheter Arterial Chemoembolization and 90Y Radioembolization in patients with Unresectable Hepatocellular Carcinoma.  Submited & Revised for JVIR. In Press.

Effect of Implantation Site and Growth of Hepatocellular Carcinoma on Apparent Diffusion Coefficient of Water and Sodium MRI Submitted & Revised for NMR in Biomedicine. In Press.

No news currently found.